Overweight
Conditions
Keywords
Satiety, Polyphenols, Fibre, Visual Analogue Scale, Cross-over, Tuna
Brief summary
The purpose of this study is to evaluate the satiating effects of different canned tuna preserved in olive oil enriched with soluble fiber or polyphenols on overweight subjects (BMI ≥25 and \<30 kg / m2). Some studies have shown the contribution of high-fiber foods in the reduction of the cardiovascular risk.
Detailed description
A randomized, cross-over and double-blind pilot study with 3 study arms is being performed to evaluate the satiating properties of different canned tuna preserved in olive oil enriched with soluble fiber or polyphenols on overweight subjects. The investigators included 12 participants (6 men and 6 women) between 18 and 55 years (BMI ≥25 and \<30 kg / m2). All volunteers will be randomized into 3 study groups, and participants will receive the 3 different study products in order during the 3 experimental phases.
Interventions
OTHERControl Canned Tuna
210 g/day
OTHEREnriched Canned Tuna Variety 1
210 g/day
OTHEREnriched Canned Tuna Variety 2
210 g/day
Sponsors
Friobas Basilio S.L.
Instituto de Investigación Hospital Universitario La Paz
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Men and women from 18 to 65 years old. * Body Mass Index (BMI) ≥25 and \<30 kg/m2. * Adequate cultural level and understanding for the clinical trial. * Signed informed consent
Exclusion criteria
* Subjects with BMI ≥30 or \<25 kg /m2 * Subjects diagnosed with Diabetes Mellitus. * Subjects with dyslipidemia on pharmacological treatment * Subjects with hypertension on pharmacological treatment * Subjects with established diagnosis of eating disorder * Smokers or those subjects with high alcohol consumption (\> 2-3 servings/ day in men and\> 1 serving/day in women (1 serving = 1 glass of wine or 1 bottle of beer) * Subjects under pharmacological treatment (except oral contraceptives) * Subjects with large weight fluctuations of more than 4 kg or who have undergone in six months a weight loss diet * Subjects with sensory problems * Subjects with gastrointestinal diseases that affect the digestion or absorption of nutrients * Pregnant or breastfeeding women * Women with menstrual irregularities (absence of menstrual cycle at least 2 months) * Subjects with intense physical activity. * Subjects with food allergies to meals included in breakfast, study product or lunch or that reject their consumption * Subjects with a diagnosis of celiac disease or a gluten intolerance
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline Satiety Hunger Assessment | Day 1, 8, 15 | Visual Analogue Scale (VAS). 100mm horizontal line anchored at each end with the extremes of the subjective feeling to be quantified. Subjects are instructed to rate the sensation being experienced according to how they define the line. e.g., not at all hungry (0mm) and as hungry as I have ever felt (100mm). Multiple measures are taken at repeated time intervals described below. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Amount of food consumed in a food ad libitum | Day 1, 8, 15 | 120 min After eating the study product |
| Total amount of food consumed in 24h | Day 1, 8, 15 | 24h Food Record Method |
| Change from Baseline Glucose Metabolism Parameters | Day 1, 8, 15 | Concentration of Glucose |
| Change from Baseline Blood Hormonal Satiety Markers | Day 1, 8, 15 | Concentration of Glucagon-like peptide-1 (GLP-1), Peptide tyrosine-tyrosine (YY), Ghrelin, Leptin, Ghrelin, Leptin, Gastric Inhibitory Peptide (GIP), Peptide C |
| Anthropometric Parameters | Day 1, 8, 15 | Weight and height will be combined to report BMI in kg/m2 |
| Sensory Perception Test | Day 1, 8, 15 | Questionnaire of analysis of sensory perception of the food study product. Five questions that are valued on a scale of 0% to 100% asking about the taste and smell of the study product: desire with which the product is taken, taste, smell, consistency and what wait for effectiveness. |
| Adverse Effects | Day 1, 8, 15 | Number of participants gastrointestinal symptoms (Nausea, Diarrhea, Bloating and other disorders) |
| Change from Baseline Lipid Metabolism Parameters | Day 1, 8, 15 | Concentration of Cholesterol, LDL-C, HDL-C, TAG |
Countries
Spain
Outcome results
None listed